METHODS OF TREATING NEURODEGENERATIVE DISEASES
First Claim
Patent Images
1. A method of treating a tauopathy comprising administering to an individual with a tauopathy a monoclonal antibody that binds human tau at a dose between 225 mg and 16800 mg, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 20;
HVR-H2 comprising the amino acid sequence of SEQ ID NO;
21;
HVR-H3 comprising the amino acid sequence of SEQ ID NO;
22;
HVR-L1 comprising the amino acid sequence of SEQ ID NO;
23;
HVR-L2 comprising the amino acid sequence of SEQ ID NO;
24; and
HVR-L3 comprising the amino acid sequence of SEQ ID NO;
25.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods of treating tauopathies with anti-Tau antibodies.
-
Citations
67 Claims
-
1. A method of treating a tauopathy comprising administering to an individual with a tauopathy a monoclonal antibody that binds human tau at a dose between 225 mg and 16800 mg, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 20;
HVR-H2 comprising the amino acid sequence of SEQ ID NO;
21;
HVR-H3 comprising the amino acid sequence of SEQ ID NO;
22;
HVR-L1 comprising the amino acid sequence of SEQ ID NO;
23;
HVR-L2 comprising the amino acid sequence of SEQ ID NO;
24; and
HVR-L3 comprising the amino acid sequence of SEQ ID NO;
25. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24, 26, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)
- 20;
-
10. (canceled)
-
12. (canceled)
-
13. (canceled)
-
16. (canceled)
-
25. (canceled)
-
27. A method of retaining or increasing one or more of memory capacity, memory function, or cognitive function or slowing memory loss in an individual, comprising administering to an individual with a tauopathy a monoclonal antibody that binds human tau at a dose between 225 mg and 16800 mg, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 20;
HVR-H2 comprising the amino acid sequence of SEQ ID NO;
21;
HVR-H3 comprising the amino acid sequence of SEQ ID NO;
22;
HVR-L1 comprising the amino acid sequence of SEQ ID NO;
23;
HVR-L2 comprising the amino acid sequence of SEQ ID NO;
24; and
HVR-L3 comprising the amino acid sequence of SEQ ID NO;
25.
- 20;
-
28-34. -34. (canceled)
-
35. A method of reducing the level of Tau protein, non-phosphorylated Tau protein, phosphorylated Tau protein, or hyperphosphorylated Tau protein in an individual, comprising administering to an individual with a tauopathy a monoclonal antibody that binds human tau at a dose between 225 mg and 16800 mg, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 20;
HVR-H2 comprising the amino acid sequence of SEQ ID NO;
21;
HVR-H3 comprising the amino acid sequence of SEQ ID NO;
22;
HVR-L1 comprising the amino acid sequence of SEQ ID NO;
23;
HVR-L2 comprising the amino acid sequence of SEQ ID NO;
24; and
HVR-L3 comprising the amino acid sequence of SEQ ID NO;
25.
- 20;
-
36-53. -53. (canceled)
-
66. (canceled)
-
67. (canceled)
Specification